292 related articles for article (PubMed ID: 29675948)
1. Pattern of care and survival of anaplastic lymphoma kinase rearranged non-small cell lung cancer (ALK+ NSCLC) in an Australian Metropolitan Tertiary Referral Centre: A retrospective cohort analysis.
Itchins M; Hayes SA; Gill AJ; Cooper W; O'Connell R; Howell VM; Clarke SJ; Pavlakis N
Asia Pac J Clin Oncol; 2018 Oct; 14(5):e275-e282. PubMed ID: 29675948
[TBL] [Abstract][Full Text] [Related]
2. Real world experience of treatment and outcome in ALK-rearranged metastatic nonsmall cell lung cancer: A multicenter study from India.
Patel A; Batra U; Prasad KT; Dabkara D; Ghosh J; Sharma M; Singh N; Suresh P; Jain P; Malik PS; Choudhary P; Ganguly S; Khurana S; Ms S; Bothra S; Muthu V; Biswas B
Curr Probl Cancer; 2020 Jun; 44(3):100571. PubMed ID: 32234264
[TBL] [Abstract][Full Text] [Related]
3. Clinical outcomes of advanced non-small-cell lung cancer patients with EGFR mutation, ALK rearrangement and EGFR/ALK co-alterations.
Lou NN; Zhang XC; Chen HJ; Zhou Q; Yan LX; Xie Z; Su J; Chen ZH; Tu HY; Yan HH; Wang Z; Xu CR; Jiang BY; Wang BC; Bai XY; Zhong WZ; Wu YL; Yang JJ
Oncotarget; 2016 Oct; 7(40):65185-65195. PubMed ID: 27533086
[TBL] [Abstract][Full Text] [Related]
4. Impact of TP53 mutation status on systemic treatment outcome in ALK-rearranged non-small-cell lung cancer.
Kron A; Alidousty C; Scheffler M; Merkelbach-Bruse S; Seidel D; Riedel R; Ihle MA; Michels S; Nogova L; Fassunke J; Heydt C; Kron F; Ueckeroth F; Serke M; Krüger S; Grohe C; Koschel D; Benedikter J; Kaminsky B; Schaaf B; Braess J; Sebastian M; Kambartel KO; Thomas R; Zander T; Schultheis AM; Büttner R; Wolf J
Ann Oncol; 2018 Oct; 29(10):2068-2075. PubMed ID: 30165392
[TBL] [Abstract][Full Text] [Related]
5. Real-world anaplastic lymphoma kinase (ALK) rearrangement testing patterns, treatment sequences, and survival of ALK inhibitor-treated patients.
Davies J; Martinec M; Coudert M; Delmar P; Crane G
Curr Med Res Opin; 2019 Mar; 35(3):535-542. PubMed ID: 30296185
[TBL] [Abstract][Full Text] [Related]
6. Natural History and Factors Associated with Overall Survival in Stage IV ALK-Rearranged Non-Small Cell Lung Cancer.
Pacheco JM; Gao D; Smith D; Purcell T; Hancock M; Bunn P; Robin T; Liu A; Karam S; Gaspar L; Kavanagh B; Rusthoven C; Aisner D; Doebele R; Camidge DR
J Thorac Oncol; 2019 Apr; 14(4):691-700. PubMed ID: 30599201
[TBL] [Abstract][Full Text] [Related]
7. Progression-Free and Overall Survival of Patients With ALK Rearrangement-Positive Non-Small Cell Lung Cancer Treated Sequentially With Crizotinib and Alectinib.
Watanabe S; Hayashi H; Okamoto K; Fujiwara K; Hasegawa Y; Kaneda H; Tanaka K; Takeda M; Nakagawa K
Clin Lung Cancer; 2016 Nov; 17(6):528-534. PubMed ID: 27318655
[TBL] [Abstract][Full Text] [Related]
8. Optimal timing and clinical value of radiotherapy in advanced ALK-rearranged non-small cell lung cancer with or without baseline brain metastases: implications from pattern of failure analyses.
Ni J; Li G; Yang X; Chu L; Wang J; Li Y; Zou L; Li Y; Xie C; Zhu Z
Radiat Oncol; 2019 Mar; 14(1):44. PubMed ID: 30866974
[TBL] [Abstract][Full Text] [Related]
9. Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1/2 trial.
Gettinger SN; Bazhenova LA; Langer CJ; Salgia R; Gold KA; Rosell R; Shaw AT; Weiss GJ; Tugnait M; Narasimhan NI; Dorer DJ; Kerstein D; Rivera VM; Clackson T; Haluska FG; Camidge DR
Lancet Oncol; 2016 Dec; 17(12):1683-1696. PubMed ID: 27836716
[TBL] [Abstract][Full Text] [Related]
10. Alectinib versus Crizotinib in Untreated ALK-Positive Non-Small-Cell Lung Cancer.
Peters S; Camidge DR; Shaw AT; Gadgeel S; Ahn JS; Kim DW; Ou SI; Pérol M; Dziadziuszko R; Rosell R; Zeaiter A; Mitry E; Golding S; Balas B; Noe J; Morcos PN; Mok T;
N Engl J Med; 2017 Aug; 377(9):829-838. PubMed ID: 28586279
[TBL] [Abstract][Full Text] [Related]
11. Low ALK FISH positive metastatic non-small cell lung cancer (NSCLC) patients have shorter progression-free survival after treatment with ALK inhibitors.
Toruner GA; Tang Z; Tang G; Medeiros LJ; Hu S
Cancer Genet; 2020 Feb; 241():57-60. PubMed ID: 31870845
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in China.
Xing P; Wang S; Wang Q; Ma D; Hao X; Wang M; Wang Y; Shan L; Xin T; Liang L; Liang H; Du Y; Zhang Z; Li J
Target Oncol; 2019 Jun; 14(3):325-333. PubMed ID: 31025247
[TBL] [Abstract][Full Text] [Related]
13. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
[TBL] [Abstract][Full Text] [Related]
14. Characteristics, treatment patterns, and survival among ALK+ non-small cell lung cancer (NSCLC) patients treated with crizotinib: A chart review study.
Cadranel J; Park K; Arrieta O; Pless M; Bendaly E; Patel D; Sasane M; Nosal A; Swallow E; Galebach P; Kageleiry A; Stein K; Degun R; Zhang J
Lung Cancer; 2016 Aug; 98():9-14. PubMed ID: 27393500
[TBL] [Abstract][Full Text] [Related]
15. Overall Survival of Patients With
Tsimafeyeu I; Moiseenko F; Orlov S; Filippova E; Belonogov A; Nebesnykh A; Khalimov A; Karabina E; Shikina V; Abdelgafur A; Statsenko G; Titova I; Isaichikov D; Makarnyaeva G; Mordovskiy A; Barkovskaya O; Smirnov A; Gikalo M; Savelov N; Kosov D; Imyanitov E; Demidova I; Tjulandin S
J Glob Oncol; 2019 May; 5():1-7. PubMed ID: 31095455
[TBL] [Abstract][Full Text] [Related]
16. Crizotinib in advanced non-small-cell lung cancer with concomitant ALK rearrangement and c-Met overexpression.
Chen RL; Zhao J; Zhang XC; Lou NN; Chen HJ; Yang X; Su J; Xie Z; Zhou Q; Tu HY; Zhong WZ; Yan HH; Guo WB; Wu YL; Yang JJ
BMC Cancer; 2018 Nov; 18(1):1171. PubMed ID: 30477470
[TBL] [Abstract][Full Text] [Related]
17. Characteristics and outcomes of ALK+ non-small cell lung cancer patients in Korea.
Lim SH; Yoh KA; Lee JS; Ahn MJ; Kim YJ; Kim SH; Zhang J; Patel D; Swallow E; Kageleiry A; Galebach P; Lee D; Stein K; Degun R; Park K
Asia Pac J Clin Oncol; 2017 Oct; 13(5):e239-e245. PubMed ID: 28419723
[TBL] [Abstract][Full Text] [Related]
18. Ceritinib versus chemotherapy in patients with ALK-rearranged non-small-cell lung cancer previously given chemotherapy and crizotinib (ASCEND-5): a randomised, controlled, open-label, phase 3 trial.
Shaw AT; Kim TM; Crinò L; Gridelli C; Kiura K; Liu G; Novello S; Bearz A; Gautschi O; Mok T; Nishio M; Scagliotti G; Spigel DR; Deudon S; Zheng C; Pantano S; Urban P; Massacesi C; Viraswami-Appanna K; Felip E
Lancet Oncol; 2017 Jul; 18(7):874-886. PubMed ID: 28602779
[TBL] [Abstract][Full Text] [Related]
19. Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
Nakamura M; Kageyama SI; Niho S; Okumura M; Hojo H; Motegi A; Nakamura N; Zenda S; Yoh K; Goto K; Akimoto T
Clin Lung Cancer; 2019 May; 20(3):e256-e264. PubMed ID: 30926356
[TBL] [Abstract][Full Text] [Related]
20. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
